cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 A new drug combo of (GLP-1 receptor agonist) with (amylin analogue) failed to do as well as tirzepatide (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Cagrilintide–semaglutide (CagriSema) as an add-on

(1,2) Meet glutathione: The master antioxidant The reason glutathione has earned this nickname is because it protects virtually every cell from damage from oxidative stress

Oral supplements ought to be taken under a doctors supervision

doi: 10.1530/EC-23-0005 PMID: 37159343 Pronunciation: kan-a-gli-FLOE-zin Dapagliflozin (Farxiga ) Trade Names: Farxiga (Forxiga in Europe) Drug Class: Anti-diabetic drug, Hypoglycemic, SGLT-2 inhibitor, Gliflozin Pharmacology is similar to canagliflozin, the other SGLT-2 inhibitor in this drug class Mechanism of Action: Hypoglycemic : Inhibits the Na-glucose co-transporter 2 (SGLT-2) in the kidney to reduce glucose reabsorption, resulting in increased urinary glucose excretion, and lower plasma glucose

Metabolic Disease: Insulin resistance, obesity, and T2D research via AMPK and mitochondrial pathway modulation